Wellfully Ltd
ASX:WFL
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
AU |
Wellfully Ltd
ASX:WFL
|
1.5m AUD | -98.9 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 436.7 | |
US |
Eli Lilly and Co
NYSE:LLY
|
767.8B USD | 208.8 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 44.3 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 923.9 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
353.7B USD | 15.3 | ||
US |
Merck & Co Inc
NYSE:MRK
|
327.9B USD | 22.2 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
190.6B GBP | 24.9 | ||
CH |
Roche Holding AG
SIX:ROG
|
183.7B CHF | 11.4 | ||
CH |
Novartis AG
SIX:NOVN
|
179.4B CHF | 14.3 | ||
US |
Pfizer Inc
NYSE:PFE
|
163.7B USD | 19.1 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.